Compare JBS N.V. Class A Common Shares (JBS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JBS N.V. Class A Common Shares vs Sanofi SA — how do they compare? JBS N.V. Class A Common Shares trades at $13.02 (market cap $13.96B), while Sanofi SA trades at $40.62 (market cap $96.38B). The key difference: Sanofi SA is far larger — about 6.9× JBS N.V. Class A Common Shares's market cap, and JBS N.V. Class A Common Shares pays the higher dividend (10.31%). Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and Sanofi SA for 94 Days on average.
| JBS | SNY | |
|---|---|---|
Market Cap | $13.96B | $96.38B |
Volume | 5,326,589 | 5,335,342 |
Sector | Consumer Staples | Health |
52-Week High | $18.42 | $52.34 |
52-Week Low | $10.86 | $39.12 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $34.93B | $115.67B |
Dividend Yield | 10.31% | 6.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Sanofi (SNY) trades at $39.12, down 1.56% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with $46.72B revenue, 16.72% net margin, and reasonable valuation (P/E 21.71). Recent expansion of the Regeneron immunology alliance worth up to $8B signals growth potential beyond Dupixent, though 2026 forecasts indicate profit margin compression to 8.09%.
SNY presents a mixed outlook with strong current execution offset by future margin pressures. The bullish analyst consensus (44% Buy) and expanding immunology pipeline provide upside catalysts, while patent expirations and competitive threats pose medium-term risks. Cash flow volatility and debt levels require monitoring for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
